Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | KCNH2 known ✓ | Q12809 | 5/20 | 0.46 |
| ▸ | OPRM1 known ✓ | P35372 | 2/20 | 0.42 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.42 |
| ▸ | OPRD1 known ✓ | P41143 | 1/20 | 0.42 |
| ▸ | PRKD3 known ✓ | O94806 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.46 |
| ▸ | ALB | P02768 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.46 |
| ▸ | TUBB | P07437 | 1/20 | 0.46 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL967999 | 0.93 | LMNA (0.72) | LMNAAADATKDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL3965168 | 0.92 | LMNA (0.69) | LMNAAADATKDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL3965173 | 0.92 | LMNA (0.69) | LMNAAADATKDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL4410375 | 0.92 | LMNA (0.69) | LMNAAADATKDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL3968769 | 0.92 | LMNA (0.73) | LMNAAADATKDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL966483 | 0.92 | LMNA (0.73) | LMNAAADATKDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL3968764 | 0.92 | LMNA (0.73) | LMNAAADATKDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL3965024 | 0.92 | LMNA (0.73) | LMNAAADATKDM4ESMN1; SMN2CYP1A2 | |
| Acetic Acid SCHEMBL3970333 | 0.90 | LMNA (0.71) | LMNAAADATKDM4ESMN1; SMN2CYP1A2 | |
| Acetic Acid SCHEMBL3970329 | 0.90 | LMNA (0.71) | LMNAAADATKDM4ESMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1175217-B8 | (S)-BENZOQUINOLIZINE CARBOXYLIC ACIDS AND THEIR USE AS ANTIBACTERIAL AGENTS | WOCKHARDT LTD (IN) | 2009-03-18 | — | — | EP | claimed |
| EP-2030620-A1 | (s)-benzoquinolizine carboxylic acids and their use as antibacterial agents | Wockhardt Limited (IN) | 2009-03-04 | — | — | EP | claimed |
| US-20080108646-A1 | Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment | WOCKHARDT LIMITED | 2008-05-08 | — | — | US | claimed |
| US-6750224-B1 | USED TO SYSTEMICALLY AND TOPICALLY TREAT BACTERIAL GRAM-POSITIVE, GRAM-NEGATIVE AND ANAEROBIC INFECTIONS, ESPECIALLY RESISTANT MYCOBACTERIAL INFECTIONS AND EMERGING NOSOCOMIAL PATHOGEN INFECTIONS | WOCKHARDT LIMITED (IN) | 2004-06-15 | — | — | US | claimed |
| US-20030207908-A1 | Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment | WOCKHARDT LIMITED (IN) | 2003-11-06 | — | — | US | claimed |
| EP-1175217-A2 | (S)-BENZOQUINOLIZINE CARBOXYLIC ACIDS AND THEIR USE AS ANTIBACTERIAL AGENTS | Wockhardt Limited (IN) | 2002-01-30 | — | — | EP | claimed |
| WO-2000068229-A2 | (S)-BENZOQUINOLIZINE CARBOXYLIC ACIDS AND THEIR USE AS ANTIBACTERIAL AGENTS | WOCKHARDT LIMITED (IN) | 2000-11-16 | — | — | WO | claimed |
| US-8507519-B2 | Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment | WOCKHARDT LIMITED (IN) | 2013-08-13 | — | — | US | disclosed |
| EP-2030620-A1 | (s)-benzoquinolizine carboxylic acids and their use as antibacterial agents | Wockhardt Limited (IN) | 2009-03-04 | — | — | EP | disclosed |
| US-20080108646-A1 | Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment | WOCKHARDT LIMITED | 2008-05-08 | — | — | US | disclosed |
| US-20080044466-A1 | Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment | WOCKHARDT LIMITED | 2008-02-21 | — | — | US | disclosed |
| US-7247642-B2 | Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment | WOCKHARDT LIMITED (IN) | 2007-07-24 | — | — | US | disclosed |
| US-6750224-B1 | USED TO SYSTEMICALLY AND TOPICALLY TREAT BACTERIAL GRAM-POSITIVE, GRAM-NEGATIVE AND ANAEROBIC INFECTIONS, ESPECIALLY RESISTANT MYCOBACTERIAL INFECTIONS AND EMERGING NOSOCOMIAL PATHOGEN INFECTIONS | WOCKHARDT LIMITED (IN) | 2004-06-15 | — | — | US | disclosed |
| US-20030207908-A1 | Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment | WOCKHARDT LIMITED (IN) | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207908-A1 | Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment | RPS27L, HBZ, WIZ | HRH3 982/4885KCNH2 3073/4885OPRM1 15/4885 |
| US-20080108646-A1 | Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment | CRYZ, SQLE, SDHA | HRH3 1087/4885KCNH2 1622/4885OPRM1 474/4885 |
| US-20080044466-A1 | Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment | CRYZ, SQLE, SDHA | HRH3 1087/4885KCNH2 1622/4885OPRM1 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.